EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Overall Survival With Circulating Tumor Cell Count–Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial

François-Clément Bidard iD, Nicolas Kiavue iD, William Jacot iD, Thomas Bachelot iD, Sylvain Dureau, Hugues Bourgeois iD, Anthony Goncalves iD, Etienne Brain iD, Sylvain Ladoire iD, Florence Dalenc, Joseph Gligorov iD, Luis Teixeira iD und 8 weitere

Journal of Clinical Oncology · 01.02.2024 · 42 (4) · 383-389

DOI: 10.1200/jco.23.00456 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.02.2024. Verfasst von François-Clément Bidard und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, INSERM CIC 1428, Institut Curie, Paris and Saint-Cloud, France. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplastic Cells, Circulating. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. In patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer, the STIC CTC trial established that, for choosing between endocrine therapy (ET) or chemotherapy, the use of circulating tumor cell (CTC) count is noninferior to the investigator's choice in terms of progression-free survival. Here, we report overall survival (OS) results, a secondary end point. Patients were randomly assigned in a 1:1 ratio to have their first-line treatment (ET or chemotherapy) determined by investigators or CTC count (chemotherapy if ≥ 5 CTCs/7.5 mL; ET if low CTC count; CellSearch). OS was assessed at the discontinuation of follow-up. After a median follow-up of 4.7 years, 382 deaths (50.6%) had occurred among 755 patients. Median OS was 51.3 months (95% CI, 46.8 to 55.1) in the CTC arm and 45.5 months (95% CI, 40.9 to 51.1) in the standard arm (hazard ratio [HR] for death, 0.85; 95% CI, 0.69 to 1.03; P = .11). Among 189 patients (25.0%) with ET recommended by clinicians and high CTC count, chemotherapy was superior to ET (HR for death, 0.53; 95% CI, 0.36 to 0.78; P = .001). In case of a discordant estimate, OS data demonstrate the clinical utility of CTC count.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoplastic Cells, CirculatingHumansFemalePrognosisProgression-Free SurvivalProportional Hazards ModelsAntineoplastic Combined Chemotherapy Protocols

Autor:innen und Institutionen

  • Department of Medical Oncology, INSERM CIC 1428, Institut Curie, Paris and Saint-Cloud, France.
  • Université de Versailles Saint-Quentin, Université Paris-Saclay, Saint-Cloud, France.
  • Department of Medical Oncology, Institut du Cancer Montpellier (ICM), Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Montpellier, France.
  • Department of Medical Oncology, Centre Léon Bérard, Lyon, France.
  • Department of Biostatistics, Institut Curie, PSL Research University, Saint-Cloud, France.
  • Department of Medical Oncology, Victor Hugo Clinic, Le Mans, France.

ORCID-Profile: François-Clément Bidard, Nicolas Kiavue, William Jacot, Thomas Bachelot, Hugues Bourgeois, Anthony Goncalves, Etienne Brain, Sylvain Ladoire, Joseph Gligorov, Luis Teixeira, Luc Cabel, Amir Kadi, Véronique Diéras

Zitieren

APA

Bidard, F. C., Kiavue, N., Jacot, W., Bachelot, T., Dureau, S., Bourgeois, H., Goncalves, A., Brain, E., Ladoire, S., Dalenc, F., Gligorov, J., Teixeira, L., Emile, G., Ferrero, J. M., Loirat, D., Cabel, L., Kadi, A., Diéras, V., Alix-Panabières, C., & Pierga, J. Y. (2024). Overall Survival With Circulating Tumor Cell Count–Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial. Journal of Clinical Oncology, 42(4), 383-389. https://doi.org/10.1200/jco.23.00456

Vancouver

Bidard FC, Kiavue N, Jacot W, Bachelot T, Dureau S, Bourgeois H, et al. Overall Survival With Circulating Tumor Cell Count–Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial. Journal of Clinical Oncology. 2024;42(4):383-389. doi:10.1200/jco.23.00456

BibTeX
@article{Bidard2024,
  author = {Bidard, François-Clément and Kiavue, Nicolas and Jacot, William and Bachelot, Thomas and Dureau, Sylvain and Bourgeois, Hugues and Goncalves, Anthony and Brain, Etienne and Ladoire, Sylvain and Dalenc, Florence and Gligorov, Joseph and Teixeira, Luis and Emile, George and Ferrero, Jean-Marc and Loirat, Delphine and Cabel, Luc and Kadi, Amir and Diéras, Véronique and Alix-Panabières, Catherine and Pierga, Jean-Yves},
  title = {Overall Survival With Circulating Tumor Cell Count–Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {4},
  pages = {383--389},
  doi = {10.1200/jco.23.00456}
}
Kostenlos starten →